<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011802</url>
  </required_header>
  <id_info>
    <org_study_id>5568</org_study_id>
    <nct_id>NCT02011802</nct_id>
  </id_info>
  <brief_title>Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision</brief_title>
  <acronym>SORKYSA</acronym>
  <official_title>Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INRESA Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sinus pilonidal concern 26/100 000 young adults. It manifests after puberty, presenting as
      an acute abscess in approximately 50% of patients or as a discharging painful sinus.
      Patients may experience lengthy healing times resulting in considerable morbidity and
      disruption to a young adult's life. Eradication of pilonidal sinus is based on a wide
      surgical excision and at the end of the procedure, the wound is dressed with an alginate
      dressing (Algosteril®).

      The objective is to show a better efficiency of Sorbact TM (trademark) dressings compared to
      Alginates that are standardized dressings after pilonidal sinus excision during a period of
      75 days. The main objective is to show a difference of 20% of wounds completely healed in 75
      days between the two types of dressing: 50% of wounds healed with Algosteril TM compared to
      70% of wounds healed with Sorbact TM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of wounds healed</measure>
    <time_frame>75 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total surface area measure of non-healed wounds</measure>
    <time_frame>75 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain</measure>
    <time_frame>every 2 weeks, from randomization up to 4 months or date of healing, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesic use</measure>
    <time_frame>every 2 weeks, from randomization up to 4 months or date of healing, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotics use</measure>
    <time_frame>every 2 weeks, from randomization up to 4 months or date of healing, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of dressings used</measure>
    <time_frame>every 2 weeks, from randomization up to 4 months or date of healing, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Sinus Pilonidal</condition>
  <arm_group>
    <arm_group_label>Algosteril TM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorbact TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algosteril TM</intervention_name>
    <arm_group_label>Algosteril TM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sorbact TM</intervention_name>
    <arm_group_label>Sorbact TM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman over 18 years old

          -  Informed consent signed by the participant

          -  Affiliation to social security system

          -  Having a pilonidal sinus:

               -  Asymptomatic or discovered by the patient during a routine examination

               -  With chronic recurrent infection and skin rupture

        Exclusion Criteria:

          -  Patients with concomitant pathology:

               -  cancer treated by chemotherapy

               -  Hypertension uncontrolled systolic blood pressure&gt;180 mmHg or diastolic&gt; 110
                  mmHg

               -  Severe comorbidity with reduced life expectancy less than 12 months

               -  Acute cardiovascular disease (myocardial infarction, stroke, recent heart
                  surgery) within 3 months before inclusion

          -  Patients participating in another clinical trial

          -  Known for intolerance to one of the dressings

          -  Known pregnancy

          -  Uncontrolled diabetes (fasting glucose &gt;2g/l)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Romain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit Romain, MD</last_name>
    <phone>0033 88 12 72 37</phone>
    <email>benoit.romain@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive-Hôpital Pasteur-39 av de la Liberté</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirema Nicolae, MD</last_name>
      <email>mirema.nicolae@ch-colmar.fr</email>
    </contact>
    <investigator>
      <last_name>Mirema Nicolae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ion ZECA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice DAVID, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive-Centre Hospitalier de Haguenau-64 av du Pr Leriche</name>
      <address>
        <city>Haguenau</city>
        <zip>67500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Bruant, MD</last_name>
      <email>paul.bruant@ch-haguenau.fr</email>
    </contact>
    <investigator>
      <last_name>Paul Bruant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive-Centre Hospitalier de Mulhouse- 20 av du Dr René Laennec</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale Viscérale et Digestive-Centre Hospitalier de Saverne-19 Côte de Saverne</name>
      <address>
        <city>Saverne</city>
        <zip>67700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive - Hôpital de Hautepierre- Hôpitaux Universitaires de Strasbourg - France</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Romain, MD</last_name>
      <phone>00 33 3 88 12 72 37</phone>
      <email>benoit.romain@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Serge ROHR, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile BRIGAND, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît ROMAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CHILINTSEVA Natalia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas KNEPFLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorbact TM</keyword>
  <keyword>Alginates</keyword>
  <keyword>Dressing</keyword>
  <keyword>Wound healing</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pilonidal Sinus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
